AbbVie Reports long-term follow-up Data for Mosunetuzumab in Idiopathic pulmonary fibrosis

AbbVie today announced long-term follow-up results for mosunetuzumab in patients with idiopathic pulmonary fibrosis. The study demonstrated that mosunetuzumab improves progression-free survival compared to standard of care or placebo. These results provide important insights into the treatment of idiopathic pulmonary fibrosis and support the continued development of mosunetuzumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.